McKesson Q4 EPS Beats, Revenue Misses

McKesson posted adjusted Q4 FY2026 earnings per share of $11.69, topping the $11.57 consensus by $0.12 for the quarter.
Revenue reached $96.3 bn, missing the $101.23 bn estimate despite a 6% year‑over‑year rise driven by oncology and multispecialty distribution.
For FY2027, McKesson guided adjusted EPS between $43.80 and $44.60, implying 12%‑14% growth versus FY2026’s $39.11 EPS per share.
Free cash flow hit $3.2 bn; $2.7 bn returned via buybacks and a $5.0 bn repurchase authorization was added, while shares fell 2%.